INTLBM
  • Home
  • Banking & Finance
  • Corporate
  • News
  • Technology
  • Blog
  • Lifestyle
  • News
  • Magazine
  • Events
  • Videos
  • Awards
  • Nomination
  • Get Listed
  • Submit Article
  • About us
  • Get In Touch
  • Sitemap
Facebook Twitter Instagram
Thursday, September 28
Facebook Twitter Instagram YouTube LinkedIn
INTLBMINTLBM
Get listed
  • BANKING & FINANCE
  • TECHNOLOGY
  • CORPORATE
  • LIFESTYLE
  • NEWS
  • BLOG
  • EVENTS
    • AWARDS 2023
  • AWARDS
  • VIDEOS
  • MAGAZINE
Facebook Twitter Instagram YouTube LinkedIn
INTLBM
You are at:Home » Angel Pharma’s IND application for mupadolimab approved by CDE

Angel Pharma’s IND application for mupadolimab approved by CDE

September 27, 2022
Facebook Twitter LinkedIn Email
Share
Facebook Twitter LinkedIn Email

Angel Pharmaceuticals Ltd. (“Angel Pharma”), a clinical-stage biopharmaceutical company, recently announced that the IND application for mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation (CDE) to initiate a Phase 1/1b clinical trial in China. Angel Pharma owns mupadolimab’s rights in Greater China.

Mupadolimab is a humanized monoclonal antibody directed against CD73 . In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. Compare with other anti-CD73 antibodies and smallmolecule drugs in development, mupadolimab is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses. Outside China, mupadolimab has been studied in combination with pembrolizumab in a Phase 1/1b trial in patients with advanced head and neck cancers and in patients with NSCLC that have failed chemotherapy and anti-PD(L)1 therapy.

Dr. Richard Miller, co-founder of Angel Pharmaceuticals, commented, “We are pleased that mupadolimab has been approved for clinical trial in China. Data from overseas clinical studies has demonstrated its safety and potential to benefit patients with advanced cancers. We look forward to working with clinical experts in China to accelerate its development.” Dr. Ted Wang, Co-founder of Angel Pharmaceuticals, commented, “We have completed the local manufacture of mupadolimab in China, and will work closely with top clinical sites to bring it to market to benefit patients in China”.

Professor Guo Ye, Deputy Secretary General of the Chinese Clinical Oncology Society (CSCO), Chairman of the Head and Neck Cancer Committee of the Chinese Clinical Oncology Society, and Department of Oncology, Shanghai East Hospital Affiliated with Tongji University, commented, “CD73 plays a key role in the formation of the immunosuppressive microenvironment in cancer, and studies have demonstrated its importance on solid tumors. Mupadolimab is a unique CD73 antibody and we hope its clinical development will progress successfully in China to benefit cancer patients.”

Source

Angel Pharmaceuticals biopharmaceutical China CSCO Dr. Richard Miller Guo Ye Mupadolimab
Share. Facebook Twitter LinkedIn Email
Previous ArticleLiiV Group onboards Vito Covalucci as Chief Product and Technology Officer
Next Article Bedu unveils Project 2117 aiming 100-million user metaverse environment

Related Posts

Shipnext secures substantial Belgian grant to boost AI in shipping

September 27, 2023

HIMA partners with NAO-Energy LLP

September 27, 2023

Innovation in the Spotlight: Most Innovative Companies of India 2023

September 26, 2023
  • Krungthai Bank
  • SC Ad banner International Business magazine website
  • Prime Point LLC Banner
Latest Posts

Acronis announces the availability of advanced automation

September 28, 2023

The Hashgraph Association partners with Dar Blockchain

September 28, 2023

Visa partners with YellowPepper and ABHI

September 28, 2023

Shipnext secures substantial Belgian grant to boost AI in shipping

September 27, 2023
International Business Magazine
International Business Magazine
About

International Business Magazine is a UAE-based online publishing company with a subscriber base of more than 50,000 that includes investors, C-suite employees, key stakeholders, policymakers and government bureaucrats. We deliver the latest news from the financial world and keenly promote innovative solutions in the industry.
Contact Us: info@intlbm.com

Socials
Facebook Twitter Instagram YouTube LinkedIn
Copyright © 2023. International Business Magazine, LLC. | ALL RIGHT RESERVED.
  • Terms & Conditions
  • Privacy Policy
  • About us
  • Get In Touch

Type above and press Enter to search. Press Esc to cancel.